Knowledge (XXG)

Ontuxizumab

Source 📝

1385: 301: 86: 1426: 403: 299:, Sass PM, Kline B, Nicolaides N, Grasso L, Harley S, "Endosialin binding molecules", published 2010-04-08, assigned to Morphotek Inc 34: 812: 1445: 1419: 1344: 1013: 1233: 396: 247: 1460: 1455: 870: 797: 702: 1412: 727: 389: 1450: 712: 817: 239:
status by the FDA for sarcoma. It is currently in phase II trials for melanoma, colorectal cancer, sarcoma, and lymphoma.
676: 143: 1361: 317:"Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications" 455: 74: 920: 267: 271: 1349: 1316: 1257: 1208: 1123: 747: 1287: 1277: 1247: 1038: 983: 910: 900: 777: 296: 1262: 1251: 1213: 1103: 1088: 1018: 998: 993: 772: 526: 1113: 973: 742: 707: 1392: 1228: 1198: 1193: 1178: 1008: 855: 807: 767: 412: 107: 44: 27: 466: 950: 501: 461: 315:
Kiyohara E, Donovan N, Takeshima L, Huang S, Wilmott JS, Scolyer RA, et al. (August 2015).
272:"International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" 243: 837: 656: 346: 49: 1396: 336: 328: 228:
is a humanized rabbit monoclonal antibody designed for the treatment of cancer. It binds to
168: 116: 152: 1355: 1321: 988: 341: 316: 1439: 1203: 1058: 611: 446: 1218: 1183: 1168: 1163: 1158: 1153: 1128: 1083: 1078: 1073: 1068: 1053: 940: 915: 895: 757: 722: 661: 641: 451: 436: 381: 367: 1300: 1295: 1267: 1243: 1238: 1173: 1148: 1138: 1108: 1098: 1063: 1048: 1033: 1023: 1003: 978: 963: 935: 885: 880: 875: 860: 850: 827: 822: 792: 737: 681: 671: 646: 636: 631: 626: 601: 576: 566: 561: 556: 546: 531: 516: 511: 496: 491: 481: 476: 471: 441: 236: 1384: 1272: 1223: 1188: 1118: 1093: 1043: 1028: 968: 958: 930: 905: 845: 787: 782: 717: 697: 651: 621: 616: 606: 596: 591: 581: 571: 541: 536: 506: 486: 332: 229: 207: 127: 1143: 1133: 925: 890: 865: 802: 762: 752: 732: 666: 586: 551: 521: 53: 20: 350: 421: 69: 61: 57: 385: 1400: 235:
Phase I trials are complete and the drug was granted
1309: 1286: 949: 836: 690: 429: 420: 206: 167: 162: 142: 126: 106: 101: 85: 80: 68: 43: 33: 26: 362: 360: 115: 1420: 397: 8: 19: 1427: 1413: 426: 404: 390: 382: 340: 151: 259: 18: 7: 1381: 1379: 248:Ludwig Institute for Cancer Research 1399:. You can help Knowledge (XXG) by 14: 374:. Springer Nature Switzerland AG. 1383: 185: 179: 1446:Drugs not assigned an ATC code 197: 191: 173: 1: 242:This drug was developed by 1477: 1378: 163:Chemical and physical data 1461:Monoclonal antibody stubs 1456:Experimental cancer drugs 1339: 921:Mirvetuximab soravtansine 333:10.1007/s12307-015-0168-8 268:World Health Organization 1317:Depatuxizumab mafodotin 1258:Tucotuzumab celmoleukin 1209:Rovalpituzumab tesirine 1124:Lorvotuzumab mertansine 1014:Clivatuzumab tetraxetan 321:Cancer Microenvironment 1395:–related article is a 1278:Vorsetuzumab mafodotin 1234:Tacatuzumab tetraxetan 1039:Denintuzumab mafodotin 984:Bivatuzumab mertansine 911:Loncastuximab tesirine 901:Indatuximab ravtansine 778:Naptumomab estafenatox 1451:Monoclonal antibodies 1263:Vandortuzumab vedotin 1214:Sacituzumab govitecan 1104:Inotuzumab ozogamicin 1089:Gemtuzumab ozogamicin 1019:Cofetuzumab pelidotin 999:Cantuzumab ravtansine 994:Cantuzumab mertansine 813:Nofetumomab merpentan 773:Moxetumomab pasudotox 527:Glembatumumab vedotin 413:Monoclonal antibodies 1310:Chimeric + humanized 1114:Lifastuzumab vedotin 974:Belantamab mafodotin 743:Ibritumomab tiuxetan 708:Anatumomab mafenatox 279:WHO Drug Information 1393:monoclonal antibody 1229:Sofituzumab vedotin 1199:Polatuzumab vedotin 1194:Pinatuzumab vedotin 1179:Oportuzumab monatox 1009:Citatuzumab bogatox 871:Derlotuximab biotin 856:Brentuximab vedotin 808:Taplitumomab paptox 798:Satumomab pendetide 768:Nacolomab tafenatox 703:Altumomab pentetate 28:Monoclonal antibody 23: 16:Monoclonal antibody 1366:Never to phase III 728:Capromab pendetide 502:Enfortumab vedotin 1408: 1407: 1376: 1375: 1335: 1334: 657:Tisotumab vedotin 232:(TEM1 or CD248). 223: 222: 1468: 1429: 1422: 1415: 1387: 1380: 1288:Rat/mouse hybrid 427: 406: 399: 392: 383: 376: 375: 364: 355: 354: 344: 312: 306: 305: 304: 300: 293: 287: 286: 276: 264: 218: 216: 199: 193: 187: 181: 175: 155: 119: 24: 22: 1476: 1475: 1471: 1470: 1469: 1467: 1466: 1465: 1436: 1435: 1434: 1433: 1377: 1372: 1371: 1356:Clinical trials 1331: 1305: 1282: 945: 832: 686: 416: 410: 380: 379: 366: 365: 358: 314: 313: 309: 302: 295: 294: 290: 274: 266: 265: 261: 256: 214: 212: 202: 196: 190: 184: 178: 158: 138: 122: 97: 17: 12: 11: 5: 1474: 1472: 1464: 1463: 1458: 1453: 1448: 1438: 1437: 1432: 1431: 1424: 1417: 1409: 1406: 1405: 1388: 1374: 1373: 1370: 1369: 1368: 1367: 1364: 1353: 1347: 1341: 1340: 1337: 1336: 1333: 1332: 1330: 1329: 1324: 1322:Duvortuxizumab 1319: 1313: 1311: 1307: 1306: 1304: 1303: 1298: 1292: 1290: 1284: 1283: 1281: 1280: 1275: 1270: 1265: 1260: 1255: 1241: 1236: 1231: 1226: 1221: 1216: 1211: 1206: 1201: 1196: 1191: 1186: 1181: 1176: 1171: 1166: 1161: 1156: 1151: 1146: 1141: 1136: 1131: 1126: 1121: 1116: 1111: 1106: 1101: 1096: 1091: 1086: 1081: 1076: 1071: 1066: 1061: 1056: 1051: 1046: 1041: 1036: 1031: 1026: 1021: 1016: 1011: 1006: 1001: 996: 991: 989:Brontictuzumab 986: 981: 976: 971: 966: 961: 955: 953: 947: 946: 944: 943: 938: 933: 928: 923: 918: 913: 908: 903: 898: 893: 888: 883: 878: 873: 868: 863: 858: 853: 848: 842: 840: 834: 833: 831: 830: 825: 820: 815: 810: 805: 800: 795: 790: 785: 780: 775: 770: 765: 760: 755: 750: 745: 740: 735: 730: 725: 720: 715: 710: 705: 700: 694: 692: 688: 687: 685: 684: 679: 674: 669: 664: 659: 654: 649: 644: 639: 634: 629: 624: 619: 614: 609: 604: 599: 594: 589: 584: 579: 574: 569: 564: 559: 554: 549: 544: 539: 534: 529: 524: 519: 514: 509: 504: 499: 494: 489: 484: 479: 474: 469: 464: 459: 456:+hyaluronidase 449: 444: 439: 433: 431: 424: 418: 417: 411: 409: 408: 401: 394: 386: 378: 377: 356: 307: 297:US 20100260769 288: 258: 257: 255: 252: 221: 220: 210: 204: 203: 200: 194: 188: 182: 176: 171: 165: 164: 160: 159: 157: 156: 148: 146: 140: 139: 137: 136: 132: 130: 124: 123: 121: 120: 112: 110: 104: 103: 99: 98: 96: 95: 91: 89: 83: 82: 78: 77: 72: 66: 65: 47: 41: 40: 39:Whole antibody 37: 31: 30: 15: 13: 10: 9: 6: 4: 3: 2: 1473: 1462: 1459: 1457: 1454: 1452: 1449: 1447: 1444: 1443: 1441: 1430: 1425: 1423: 1418: 1416: 1411: 1410: 1404: 1402: 1398: 1394: 1389: 1386: 1382: 1365: 1363: 1360: 1359: 1357: 1354: 1351: 1348: 1346: 1343: 1342: 1338: 1328: 1325: 1323: 1320: 1318: 1315: 1314: 1312: 1308: 1302: 1299: 1297: 1294: 1293: 1291: 1289: 1285: 1279: 1276: 1274: 1271: 1269: 1266: 1264: 1261: 1259: 1256: 1253: 1249: 1245: 1242: 1240: 1237: 1235: 1232: 1230: 1227: 1225: 1222: 1220: 1217: 1215: 1212: 1210: 1207: 1205: 1204:Rosmantuzumab 1202: 1200: 1197: 1195: 1192: 1190: 1187: 1185: 1182: 1180: 1177: 1175: 1172: 1170: 1167: 1165: 1162: 1160: 1157: 1155: 1152: 1150: 1147: 1145: 1142: 1140: 1137: 1135: 1132: 1130: 1127: 1125: 1122: 1120: 1117: 1115: 1112: 1110: 1107: 1105: 1102: 1100: 1097: 1095: 1092: 1090: 1087: 1085: 1082: 1080: 1077: 1075: 1072: 1070: 1067: 1065: 1062: 1060: 1059:Enoblituzumab 1057: 1055: 1052: 1050: 1047: 1045: 1042: 1040: 1037: 1035: 1032: 1030: 1027: 1025: 1022: 1020: 1017: 1015: 1012: 1010: 1007: 1005: 1002: 1000: 997: 995: 992: 990: 987: 985: 982: 980: 977: 975: 972: 970: 967: 965: 962: 960: 957: 956: 954: 952: 948: 942: 939: 937: 934: 932: 929: 927: 924: 922: 919: 917: 914: 912: 909: 907: 904: 902: 899: 897: 894: 892: 889: 887: 884: 882: 879: 877: 874: 872: 869: 867: 864: 862: 859: 857: 854: 852: 849: 847: 844: 843: 841: 839: 835: 829: 826: 824: 821: 819: 816: 814: 811: 809: 806: 804: 801: 799: 796: 794: 791: 789: 786: 784: 781: 779: 776: 774: 771: 769: 766: 764: 761: 759: 756: 754: 751: 749: 746: 744: 741: 739: 736: 734: 731: 729: 726: 724: 721: 719: 716: 714: 711: 709: 706: 704: 701: 699: 696: 695: 693: 689: 683: 680: 678: 675: 673: 670: 668: 665: 663: 660: 658: 655: 653: 650: 648: 645: 643: 640: 638: 635: 633: 630: 628: 625: 623: 620: 618: 615: 613: 612:Pembrolizumab 610: 608: 605: 603: 600: 598: 595: 593: 590: 588: 585: 583: 580: 578: 575: 573: 570: 568: 565: 563: 560: 558: 555: 553: 550: 548: 545: 543: 540: 538: 535: 533: 530: 528: 525: 523: 520: 518: 515: 513: 510: 508: 505: 503: 500: 498: 495: 493: 490: 488: 485: 483: 480: 478: 475: 473: 470: 468: 465: 463: 460: 457: 453: 450: 448: 447:Ascrinvacumab 445: 443: 440: 438: 435: 434: 432: 428: 425: 423: 419: 414: 407: 402: 400: 395: 393: 388: 387: 384: 373: 369: 368:"Ontuxizumab" 363: 361: 357: 352: 348: 343: 338: 334: 330: 326: 322: 318: 311: 308: 298: 292: 289: 284: 280: 273: 269: 263: 260: 253: 251: 249: 245: 240: 238: 233: 231: 227: 211: 209: 205: 172: 170: 166: 161: 154: 150: 149: 147: 145: 141: 134: 133: 131: 129: 125: 118: 114: 113: 111: 109: 105: 100: 93: 92: 90: 88: 84: 81:Clinical data 79: 76: 73: 71: 67: 63: 59: 55: 51: 48: 46: 42: 38: 36: 32: 29: 25: 1401:expanding it 1390: 1326: 1219:Sibrotuzumab 1184:Parsatuzumab 1169:Otlertuzumab 1164:Odronextamab 1159:Ocaratuzumab 1154:Obinutuzumab 1129:Lumretuzumab 1084:Flotetuzumab 1079:Ficlatuzumab 1074:Farletuzumab 1069:Etaracizumab 1054:Emibetuzumab 941:Zolbetuximab 916:Margetuximab 896:Girentuximab 758:Minretumomab 723:Blinatumomab 662:Teprotumumab 642:Seribantumab 467:Botensilimab 452:Atezolizumab 437:Adecatumumab 372:Adis Insight 371: 327:(2): 111–8. 324: 320: 310: 291: 282: 278: 262: 241: 234: 225: 224: 1352:from market 1327:Ontuxizumab 1301:Ertumaxomab 1296:Catumaxomab 1268:Vanucizumab 1248:+deruxtecan 1244:Trastuzumab 1239:Tigatuzumab 1174:Onartuzumab 1149:Nimotuzumab 1139:Milatuzumab 1109:Labetuzumab 1099:Imgatuzumab 1064:Epcoritamab 1049:Emactuzumab 1034:Dalotuzumab 1024:Dacetuzumab 1004:Cirmtuzumab 979:Bevacizumab 964:Alemtuzumab 936:Ublituximab 886:Ensituximab 881:Ecromeximab 876:Dinutuximab 861:Carotuximab 851:Bavituximab 828:Tositumomab 823:Tenatumomab 793:Racotumomab 738:Edrecolomab 713:Arcitumomab 682:Zalutumumab 672:Vantictumab 647:Sugemalimab 637:Robatumumab 632:Rilotumumab 627:Ramucirumab 602:Panitumumab 577:Necitumumab 567:Mapatumumab 562:Lucatumumab 557:Lexatumumab 547:Istiratumab 532:Intetumumab 517:Flanvotumab 512:Figitumumab 497:Dusigitumab 492:Duligotumab 482:Daratumumab 477:Conatumumab 472:Cixutumumab 462:Balstilimab 442:Amivantamab 237:orphan drug 226:Ontuxizumab 219: g·mol 117:946415-62-9 102:Identifiers 21:Ontuxizumab 1440:Categories 1273:Veltuzumab 1252:+emtansine 1224:Simtuzumab 1189:Pertuzumab 1119:Lintuzumab 1094:Glofitamab 1044:Elotuzumab 1029:Demcizumab 969:Axatilimab 959:Abituzumab 931:Siltuximab 906:Isatuximab 846:Amatuximab 818:Pintumomab 788:Pemtumomab 783:Oregovomab 718:Bectumomab 698:Abagovomab 652:Tarextumab 622:Radretumab 617:Pritumumab 607:Patritumab 597:Olaratumab 592:Ofatumumab 582:Nesvacumab 572:Narnatumab 542:Iratumumab 537:Ipilimumab 507:Enoticumab 487:Drozitumab 415:for tumors 254:References 230:endosialin 208:Molar mass 153:0M2XT000YC 128:ChemSpider 108:CAS Number 1362:Phase III 1350:Withdrawn 1144:Naxitamab 1134:Matuzumab 951:Humanized 926:Rituximab 891:Futuximab 866:Cetuximab 803:Solitomab 763:Mitumomab 753:Lilotomab 733:Detumomab 677:Votumumab 667:Tovetumab 587:Nivolumab 552:Icrucumab 522:Ganitumab 244:Morphotek 54:humanized 838:Chimeric 748:Igovomab 351:26085332 270:(2013). 87:ATC code 56:hybrid ( 50:Chimeric 342:4542822 169:Formula 1345:WHO-EM 349:  339:  303:  70:Target 45:Source 1391:This 691:Mouse 430:Human 422:Tumor 275:(PDF) 183:10050 62:human 58:mouse 1397:stub 347:PMID 285:(2). 246:and 195:2054 189:1726 177:6532 144:UNII 135:none 94:none 75:TEM1 35:Type 337:PMC 329:doi 217:.92 215:034 213:147 1442:: 1358:: 1250:/ 370:. 359:^ 345:. 335:. 323:. 319:. 283:27 281:. 277:. 250:. 201:44 1428:e 1421:t 1414:v 1403:. 1254:) 1246:( 458:) 454:( 405:e 398:t 391:v 353:. 331:: 325:8 198:S 192:O 186:N 180:H 174:C 64:) 60:/ 52:/

Index

Monoclonal antibody
Type
Source
Chimeric
humanized
mouse
human
Target
TEM1
ATC code
CAS Number
946415-62-9
ChemSpider
UNII
0M2XT000YC
Formula
Molar mass
endosialin
orphan drug
Morphotek
Ludwig Institute for Cancer Research
World Health Organization
"International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109"
US 20100260769
"Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications"
doi
10.1007/s12307-015-0168-8
PMC
4542822
PMID

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.